Cambium Bio Limited (ASX:CMB) is a Sydney-based clinical-stage regenerative medicine company focusing on the development of innovative biologics for ophthalmology and tissue regeneration applications. The Company's proprietary technology, based on human platelet lysate, is being leveraged to create a pipeline of novel therapeutics with a primary focus on ophthalmology. Cambium Bio's lead product candidate, Elate Ocular®, is being developed to address significant unmet medical needs in the treatment of dry eye disease. In addition, the Company's stem cell platform, Progenza™, is being applied to the development of therapies for knee osteoarthritis and other tissue repair indications. Cambium Bio is committed to advancing its pipeline through clinical development and commercialization, with the goal of providing transformative treatments to improve patient outcomes. For more information about the Company and its programs, please visit www.cambium.bio
Company Details
- Employees
- 9
- Address
- 16 Goodhope St, Paddington,new South Wales 2021,australia
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- https://cambium.bio
- Keywords
- IT Consulting.
- HQ
- Paddington, New South Wales
Cambium Bio Questions
Cambium Bio's website is https://cambium.bio
Cambium Bio's LinkedIn profile is https://au.linkedin.com/company/cambiumbio
Cambium Bio has
9 employees.
View email and phone details for 9
employees at Cambium Bio.
Cambium Bio's industry is
Biotechnology Research
Cambium Bio's top competitors are
Evithé Biotechnology,
Atticus Medical,
Regeneus Ltd,
Imugene Limited,
Cad-It Australia Pty Ltd,
Syngene International Limited,
Blinklab Limited (Asx:bb1),
Moorio,
Lachesis Biosciences,
Ezz Life Science Holdings Asx:ezz.
Cambium Bio's categories are Biotechnology Research
